Latest Information Update: 15 Aug 2016
At a glance
- Originator Beta Innov
- Class Antineoplastics
- Mechanism of Action L-lactate dehydrogenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 10 Aug 2016 Preclinical development is ongoing in France